A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas

PURPOSE: To assess the preclinical efficacy, clinical safety and efficacy, and MTD of palbociclib plus nab-paclitaxel in patients with advanced pancreatic ductal adenocarcinoma (PDAC). EXPERIMENTAL DESIGN: Preclinical activity was tested in patient-derived xenograft (PDX) models of PDAC. In the open...

Descripción completa

Detalles Bibliográficos
Autores principales: Hidalgo, Manuel, Garcia-Carbonero, Rocio, Lim, Kian-Huat, Messersmith, Wells A., Garrido-Laguna, Ignacio, Borazanci, Erkut, Lowy, Andrew M., Medina Rodriguez, Laura, Laheru, Daniel, Salvador-Barbero, Beatriz, Malumbres, Marcos, Shields, David J., Grossman, Joseph E., Huang, Xin, Tammaro, Meggan, Martini, Jean-François, Yu, Yanke, Kern, Kenneth, Macarulla, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035387/
https://www.ncbi.nlm.nih.gov/pubmed/36970055
http://dx.doi.org/10.1158/2767-9764.CRC-22-0072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035387/
https://www.ncbi.nlm.nih.gov/pubmed/36970055
http://dx.doi.org/10.1158/2767-9764.CRC-22-0072

Ejemplares similares